Skip to main content
Erschienen in: Diabetologia 9/2009

01.09.2009 | Editorial

Does diabetes therapy influence the risk of cancer?

verfasst von: U. Smith, E. A. M. Gale

Erschienen in: Diabetologia | Ausgabe 9/2009

Einloggen, um Zugang zu erhalten

Excerpt

Type 2 diabetes is associated with three of the five leading causes of cancer mortality in the USA—carcinoma of the colon, pancreas and breast (postmenopausal) [1]. The excess risk for each cancer is ~30% (colon), ~50% (pancreas) and ~20% (breast) [24]. Type 1 diabetes carries an excess cancer risk of ~20%, but involves a different range of tumours [5]. The major cancers linked with type 2 diabetes are also associated with obesity or insulin resistance, suggesting that factors other than glucose play an important role [6]. These observations, although well-attested, have attracted relatively little interest within the world of diabetes. This is partly due to the dominant role of cardiovascular disease, which largely accounts for the twofold increase in mortality associated with type 2 diabetes [7], and partly, perhaps, because cancer has seemed unavoidable. …
Literatur
1.
Zurück zum Zitat Coughlin SS et al (2004) Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 159:1160–1167PubMedCrossRef Coughlin SS et al (2004) Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 159:1160–1167PubMedCrossRef
2.
Zurück zum Zitat Larsson SC, Orsini N, Wolk A (2005) Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 97:1679–1687PubMedCrossRef Larsson SC, Orsini N, Wolk A (2005) Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 97:1679–1687PubMedCrossRef
3.
Zurück zum Zitat Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F, Woodward M (2005) Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 92:2076–2083PubMedCrossRef Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F, Woodward M (2005) Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 92:2076–2083PubMedCrossRef
4.
Zurück zum Zitat Larsson SC, Mantzoros CS, Wolk A (2007) Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer 121:856–862PubMedCrossRef Larsson SC, Mantzoros CS, Wolk A (2007) Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer 121:856–862PubMedCrossRef
5.
Zurück zum Zitat Zendehdel K, Nyrén O, Östenson C-G, Adami H-O, Ekbom A, Ye W (2003) Cancer incidence in patients with type 1 diabetes mellitus: a population-based cohort study in Sweden. J Natl Cancer Inst 95:1797–1800PubMed Zendehdel K, Nyrén O, Östenson C-G, Adami H-O, Ekbom A, Ye W (2003) Cancer incidence in patients with type 1 diabetes mellitus: a population-based cohort study in Sweden. J Natl Cancer Inst 95:1797–1800PubMed
6.
Zurück zum Zitat Giovannucci E, Michaud D (2007) The role of obesity and related metabolic disturbances in cancers of the colon, prostate and pancreas. Gastroenterology 132:2208–2225PubMedCrossRef Giovannucci E, Michaud D (2007) The role of obesity and related metabolic disturbances in cancers of the colon, prostate and pancreas. Gastroenterology 132:2208–2225PubMedCrossRef
7.
Zurück zum Zitat Mulnier HE, Seaman HE, Raleigh VS, Soedamah-Muthu SS, Colhoun HM, Lawrenson RA (2006) Mortality in people with type 2 diabetes in the UK. Diabetic Med 23:516–521PubMedCrossRef Mulnier HE, Seaman HE, Raleigh VS, Soedamah-Muthu SS, Colhoun HM, Lawrenson RA (2006) Mortality in people with type 2 diabetes in the UK. Diabetic Med 23:516–521PubMedCrossRef
8.
Zurück zum Zitat Evans JMM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ 330:1304–1305PubMedCrossRef Evans JMM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ 330:1304–1305PubMedCrossRef
9.
Zurück zum Zitat Bowker SL et al (2006) Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29:254–258PubMedCrossRef Bowker SL et al (2006) Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29:254–258PubMedCrossRef
11.
Zurück zum Zitat Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M et al (2006) Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 66:10269–10273PubMedCrossRef Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M et al (2006) Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 66:10269–10273PubMedCrossRef
12.
Zurück zum Zitat Schimmack G, DeFronzo RA, Musi N (2006) AMP-activated protein kinase: role in metabolism and therapeutic implications. Diabetes Obes Metab 8:591–602PubMedCrossRef Schimmack G, DeFronzo RA, Musi N (2006) AMP-activated protein kinase: role in metabolism and therapeutic implications. Diabetes Obes Metab 8:591–602PubMedCrossRef
13.
Zurück zum Zitat Sahra IB, Laurent K, Loubat A et al (2008) The antidiabetic drug metformin exerts an antitumour effect in vitro and in vivo through a decrease in cyclin D1 level. Oncogene 27:3576–3586PubMedCrossRef Sahra IB, Laurent K, Loubat A et al (2008) The antidiabetic drug metformin exerts an antitumour effect in vitro and in vivo through a decrease in cyclin D1 level. Oncogene 27:3576–3586PubMedCrossRef
14.
15.
Zurück zum Zitat Yang Y-X, Hennessy S, Lewis JD (2004) Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology 127:1044–1050PubMedCrossRef Yang Y-X, Hennessy S, Lewis JD (2004) Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology 127:1044–1050PubMedCrossRef
16.
Zurück zum Zitat Hsu IR, Kim SP, Kabir M, Bergman RN (2007) Metabolic syndrome, hyperinsulinemia, and cancer. Am J Clin Nutr 86:867S–871S Hsu IR, Kim SP, Kabir M, Bergman RN (2007) Metabolic syndrome, hyperinsulinemia, and cancer. Am J Clin Nutr 86:867S–871S
17.
Zurück zum Zitat Holly JMP, Perks CM (2008) Cancer as an endocrine problem. Best Pract Res Clin Endocrinol Metab 22:539–550PubMedCrossRef Holly JMP, Perks CM (2008) Cancer as an endocrine problem. Best Pract Res Clin Endocrinol Metab 22:539–550PubMedCrossRef
19.
Zurück zum Zitat Samani AA, Yakar S, LeRoith D, Brodt P (2007) The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 28:20–47PubMedCrossRef Samani AA, Yakar S, LeRoith D, Brodt P (2007) The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 28:20–47PubMedCrossRef
20.
Zurück zum Zitat Kim JJ, Accili D (2002) Signalling through IGF-1 and insulin receptors: where is the specificity? Growth Horm IGF Res 12:84–90PubMedCrossRef Kim JJ, Accili D (2002) Signalling through IGF-1 and insulin receptors: where is the specificity? Growth Horm IGF Res 12:84–90PubMedCrossRef
21.
Zurück zum Zitat Frasca F, Pandini G, Scalia P et al (1999) Insulin receptor isoform A, a newly recognised, high affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol 19:3278–3288PubMed Frasca F, Pandini G, Scalia P et al (1999) Insulin receptor isoform A, a newly recognised, high affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol 19:3278–3288PubMed
22.
Zurück zum Zitat Baserga R, Peruzzi F, Reiss K (2003) The IGF-1 receptor in cancer biology. Int J Cancer 107:873–877PubMedCrossRef Baserga R, Peruzzi F, Reiss K (2003) The IGF-1 receptor in cancer biology. Int J Cancer 107:873–877PubMedCrossRef
23.
Zurück zum Zitat Hemkens LG, Grouven U, Bender R et al (2009) Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia doi:10.1007/s00125-009-1418-4 PubMed Hemkens LG, Grouven U, Bender R et al (2009) Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia doi:10.​1007/​s00125-009-1418-4 PubMed
24.
Zurück zum Zitat Jonasson JM, Ljung R, Talbäck M, Haglund B, Gudbjörnsdòttir S, Steineck G (2009) Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden. Diabetologia. doi:10.1007/s00125-009-1444-2 Jonasson JM, Ljung R, Talbäck M, Haglund B, Gudbjörnsdòttir S, Steineck G (2009) Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden. Diabetologia. doi:10.​1007/​s00125-009-1444-2
25.
Zurück zum Zitat Colhoun HM, SDRN Epidemiology group (2009) Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia. doi:10.1007/s00125-009-1453-1 Colhoun HM, SDRN Epidemiology group (2009) Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia. doi:10.​1007/​s00125-009-1453-1
27.
29.
Zurück zum Zitat Ebeling P, Tuominen JA, Koivisto VA (1996) Insulin analogues and carcinoma of the breast. Diabetologia 39:124–125PubMed Ebeling P, Tuominen JA, Koivisto VA (1996) Insulin analogues and carcinoma of the breast. Diabetologia 39:124–125PubMed
30.
Zurück zum Zitat Hansen BF, Danielsen GM, Drejer K et al (1996) Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency. Biochem J 315:271–279PubMed Hansen BF, Danielsen GM, Drejer K et al (1996) Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency. Biochem J 315:271–279PubMed
31.
Zurück zum Zitat Slieker LJ, Brooke GS, DiMarchi RD et al (1997) Modifications in the B10 and B26–30 regions of the B chain of human insulin alter affinity for the human IGF-1 receptor more than for the insulin receptor. Diabetologia 40:S54–S61PubMedCrossRef Slieker LJ, Brooke GS, DiMarchi RD et al (1997) Modifications in the B10 and B26–30 regions of the B chain of human insulin alter affinity for the human IGF-1 receptor more than for the insulin receptor. Diabetologia 40:S54–S61PubMedCrossRef
32.
Zurück zum Zitat Jorgensen L, Dideriksen L, Drejer K (1992) Carcinogenic effect of the human insulin analogue B10Asp in female rats. Diabetologia 35(Suppl 1):A3 (Abstract) Jorgensen L, Dideriksen L, Drejer K (1992) Carcinogenic effect of the human insulin analogue B10Asp in female rats. Diabetologia 35(Suppl 1):A3 (Abstract)
33.
Zurück zum Zitat Kurtzhals P, Schäffer L, Sørensen A et al (2000) Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49:999–1005PubMedCrossRef Kurtzhals P, Schäffer L, Sørensen A et al (2000) Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49:999–1005PubMedCrossRef
34.
Zurück zum Zitat Erbel S, Büchler MW, Reers C et al (2008) Proliferation of colo-357 pancreatic carcinoma cells and survival of patients with pancreatic carcinoma are not altered by insulin glargine. Diabetes Care 31:1105–1111PubMedCrossRef Erbel S, Büchler MW, Reers C et al (2008) Proliferation of colo-357 pancreatic carcinoma cells and survival of patients with pancreatic carcinoma are not altered by insulin glargine. Diabetes Care 31:1105–1111PubMedCrossRef
35.
Zurück zum Zitat Weinstein D, Simon M, Yehezkel E, Laron Z, Werner H (2008) Insulin analogues display IGF-1-like mitogenic and anti-apoptotic activities in cultured cancer cells. Diabetes Metab Res Rev 25:41–49CrossRef Weinstein D, Simon M, Yehezkel E, Laron Z, Werner H (2008) Insulin analogues display IGF-1-like mitogenic and anti-apoptotic activities in cultured cancer cells. Diabetes Metab Res Rev 25:41–49CrossRef
36.
Zurück zum Zitat Shukla A, Grisouard J, Ehemann V, Hermani A, Enzmann H, Mayer D (2009) Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines. Endocr Relat Cancer 16:429–441PubMedCrossRef Shukla A, Grisouard J, Ehemann V, Hermani A, Enzmann H, Mayer D (2009) Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines. Endocr Relat Cancer 16:429–441PubMedCrossRef
37.
Zurück zum Zitat Kuerzel GU, Shukla U, Scholtz HE et al (2003) Biotransformation of insulin glargine after subcutaneous injection in healthy subjects. Curr Med Res Opin 19:34–40PubMedCrossRef Kuerzel GU, Shukla U, Scholtz HE et al (2003) Biotransformation of insulin glargine after subcutaneous injection in healthy subjects. Curr Med Res Opin 19:34–40PubMedCrossRef
38.
Zurück zum Zitat Agin A, Jeandidier N, Gasser F, Grucker D, Sapin R (2007) Glargine blood biotransformation: in vitro appraisal with human insulin immunoassay. Diabetes Metab 33:205–212PubMedCrossRef Agin A, Jeandidier N, Gasser F, Grucker D, Sapin R (2007) Glargine blood biotransformation: in vitro appraisal with human insulin immunoassay. Diabetes Metab 33:205–212PubMedCrossRef
39.
Zurück zum Zitat Stammberger I, Bube A, Durchfeld-Meyer B, Donaubauer H, Troschau G (2002) Evaluation of the carcinogenic potential of insulin glargine (LANTUS) in rats and mice. Int J Toxicol 21:171–179PubMedCrossRef Stammberger I, Bube A, Durchfeld-Meyer B, Donaubauer H, Troschau G (2002) Evaluation of the carcinogenic potential of insulin glargine (LANTUS) in rats and mice. Int J Toxicol 21:171–179PubMedCrossRef
41.
Zurück zum Zitat Rosenstock J, Fonseca V, McGill JB et al (2009) Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Diabetologia. doi:10.1007/s00125-009-1415-7 Rosenstock J, Fonseca V, McGill JB et al (2009) Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Diabetologia. doi:10.​1007/​s00125-009-1415-7
42.
Zurück zum Zitat Schneider MB, Matsuzaki H, Haorah J et al (2001) Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology 120:1263–1270PubMedCrossRef Schneider MB, Matsuzaki H, Haorah J et al (2001) Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology 120:1263–1270PubMedCrossRef
43.
Zurück zum Zitat Matveyenko AV, Dry S, Cox HI et al (2009) Beneficial endocrine but adverse exocrine effects of sitagliptin in the HIP rat model of type 2 diabetes, interactions with metformin. Diabetes. doi:10.2337/db09-0058 Matveyenko AV, Dry S, Cox HI et al (2009) Beneficial endocrine but adverse exocrine effects of sitagliptin in the HIP rat model of type 2 diabetes, interactions with metformin. Diabetes. doi:10.​2337/​db09-0058
44.
Zurück zum Zitat Rosenstock J, Schwartz SL, Clark CM Jr, Park GD, Donley DW, Edwards MB (2001) Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 24:631–636PubMedCrossRef Rosenstock J, Schwartz SL, Clark CM Jr, Park GD, Donley DW, Edwards MB (2001) Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 24:631–636PubMedCrossRef
45.
Zurück zum Zitat Zib I, Raskin P (2006) Novel insulin analogues and its mitogenic potential. Diabetes Obes Metab 8:611–620PubMedCrossRef Zib I, Raskin P (2006) Novel insulin analogues and its mitogenic potential. Diabetes Obes Metab 8:611–620PubMedCrossRef
46.
Zurück zum Zitat Shaw LC, Grant MB (2004) Insulin like growth factor-1 and insulin-like growth factor binding proteins: their possible roles in both maintaining normal retinal vascular function and in promoting retinal pathology. Rev Endocr Metab Disord 5:199–207PubMedCrossRef Shaw LC, Grant MB (2004) Insulin like growth factor-1 and insulin-like growth factor binding proteins: their possible roles in both maintaining normal retinal vascular function and in promoting retinal pathology. Rev Endocr Metab Disord 5:199–207PubMedCrossRef
47.
Zurück zum Zitat Black N (1996) Why we need observational studies. BMJ 312:1215–1218PubMed Black N (1996) Why we need observational studies. BMJ 312:1215–1218PubMed
48.
Zurück zum Zitat Papanikolaou PN, Christidi GD, Ioannidis JP (2006) Comparision of evidence on harms of medical interventions in randomized and non-randomized studies. CMAJ 174:635–641PubMed Papanikolaou PN, Christidi GD, Ioannidis JP (2006) Comparision of evidence on harms of medical interventions in randomized and non-randomized studies. CMAJ 174:635–641PubMed
49.
Zurück zum Zitat Holleman F, Gale EAM (2007) Nice insulins, pity about the evidence. Diabetologia 50:1783–1790PubMedCrossRef Holleman F, Gale EAM (2007) Nice insulins, pity about the evidence. Diabetologia 50:1783–1790PubMedCrossRef
50.
Zurück zum Zitat Horvath K, Jeitler K, Berghold A, Ebrahim SH, Gratzer TW et al (2007) Long-acting insulin analogues vs NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev issue 2:art. no. CD005613. doi:10.1002/14651858.CD005613.pub3. Horvath K, Jeitler K, Berghold A, Ebrahim SH, Gratzer TW et al (2007) Long-acting insulin analogues vs NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev issue 2:art. no. CD005613. doi:10.​1002/​14651858.​CD005613.​pub3.
51.
Zurück zum Zitat Nathan DM, Buse JM, Davidson MB et al (2009) Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 52:17–30PubMedCrossRef Nathan DM, Buse JM, Davidson MB et al (2009) Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 52:17–30PubMedCrossRef
52.
Zurück zum Zitat Singh SR, Ahmad F, Lal A, Yu C, Bai Z, Bennett H (2009) Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. CMAJ 180:385–397PubMed Singh SR, Ahmad F, Lal A, Yu C, Bai Z, Bennett H (2009) Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. CMAJ 180:385–397PubMed
53.
Zurück zum Zitat Barone BB, Yeh H-C, Snyder CF et al (2008) Long-term all-cause mortality in cancer patients with pre-existing diabetes mellitus. A systematic review and meta-analysis. JAMA 300:2754–2764PubMedCrossRef Barone BB, Yeh H-C, Snyder CF et al (2008) Long-term all-cause mortality in cancer patients with pre-existing diabetes mellitus. A systematic review and meta-analysis. JAMA 300:2754–2764PubMedCrossRef
54.
Zurück zum Zitat Frayling TM, Colhoun H, Florez JC (2008) A genetic link between type 2 diabetes and prostate cancer. Diabetologia 51:1757–1760PubMedCrossRef Frayling TM, Colhoun H, Florez JC (2008) A genetic link between type 2 diabetes and prostate cancer. Diabetologia 51:1757–1760PubMedCrossRef
Metadaten
Titel
Does diabetes therapy influence the risk of cancer?
verfasst von
U. Smith
E. A. M. Gale
Publikationsdatum
01.09.2009
Verlag
Springer-Verlag
Erschienen in
Diabetologia / Ausgabe 9/2009
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-009-1441-5

Weitere Artikel der Ausgabe 9/2009

Diabetologia 9/2009 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.